The SCALE (Satiety and Clinical AdiposityLiraglutide Evidence) study comprised a series of Phase 3 trials evaluating the efficacy of Liraglutide 3 mg in diverse populations, including general obese patients, as well as those with pre-diabetes, diabetes, and sleep apnea syndrome 10,11,12,13,14,15
There was no significant difference in adverse effects between treatment groups
The peptide works through multiple pathways: stimulating angiogenesis (new blood vessel formation), enhancing osteoblast activity, and reducing inflammation at injury sites
It still presents many avenues for further research, such as long-term cardiovascular benefits and safety
With its natural ingredients and antioxidant properties, it not only helps to lighten the skin but also has anti-aging benefits
This approach enables highly sensitive measurements across diverse biological samples, including blood, urine, and tissue fluids, supporting large-scale cohort studies, disease subtype stratification, and early diagnosis